BACKGROUND: Studies have demonstrated that mRNA-based SARS-CoV-2 vaccines are highly effective among patients on dialysis. Because individual vaccines may be differentially available or acceptable to patients, it is important to understand comparative effectiveness relative to other vaccines, such those on the basis of adenovirus technologies. METHODS: In this retrospective study, we compared the clinical effectiveness of adenovirus vector-based Ad26.COV2.S (Janssen/Johnson & Johnson) to mRNA-based BNT162b2 (Pfizer/BioNTech) in a contemporary cohort of patients on dialysis. Patients who received a first BNT162b2 dose were matched 1:1 to Ad26.COV2.S recipients on the basis of date of first vaccine receipt, US state of residence, site of dialysis care (in-center versus home), history of COVID-19, and propensity score. The primary outcome was the comparative rate of COVID-19 diagnoses starting in the 7th week postvaccination. In a subset of consented patients who received Ad26.COV2.S, blood samples were collected ≥28 days after vaccination and anti-SARS-CoV-2 immunoglobulin G antibodies were measured. RESULTS: A total of 2572 matched pairs of patients qualified for analysis. Cumulative incidence rates of COVID-19 did not differ for BNT162b2 versus Ad26.COV2.S. No differences were observed in peri-COVID-19 hospitalizations and deaths among patients receiving BNT162b2 versus Ad26.COV2.S, who were diagnosed with COVID-19 during the at-risk period. Results were similar when excluding patients with a history of COVID-19, in subgroup analyses restricted to patients who completed the two-dose BNT162b2 regimen, and in patients receiving in-center hemodialysis. SARS-CoV-2 antibodies were detected in 59.4% of 244 patients who received Ad26.COV2.S. CONCLUSIONS: In a large real-world cohort of patients on dialysis, no difference was detected in clinical effectiveness of BNT162b2 and Ad26.COV2.S over the first 6 months postvaccination, despite an inconsistent antibody response to the latter.
BACKGROUND: Studies have demonstrated that mRNA-based SARS-CoV-2 vaccines are highly effective among patients on dialysis. Because individual vaccines may be differentially available or acceptable to patients, it is important to understand comparative effectiveness relative to other vaccines, such those on the basis of adenovirus technologies. METHODS: In this retrospective study, we compared the clinical effectiveness of adenovirus vector-based Ad26.COV2.S (Janssen/Johnson & Johnson) to mRNA-based BNT162b2 (Pfizer/BioNTech) in a contemporary cohort of patients on dialysis. Patients who received a first BNT162b2 dose were matched 1:1 to Ad26.COV2.S recipients on the basis of date of first vaccine receipt, US state of residence, site of dialysis care (in-center versus home), history of COVID-19, and propensity score. The primary outcome was the comparative rate of COVID-19 diagnoses starting in the 7th week postvaccination. In a subset of consented patients who received Ad26.COV2.S, blood samples were collected ≥28 days after vaccination and anti-SARS-CoV-2 immunoglobulin G antibodies were measured. RESULTS: A total of 2572 matched pairs of patients qualified for analysis. Cumulative incidence rates of COVID-19 did not differ for BNT162b2 versus Ad26.COV2.S. No differences were observed in peri-COVID-19 hospitalizations and deaths among patients receiving BNT162b2 versus Ad26.COV2.S, who were diagnosed with COVID-19 during the at-risk period. Results were similar when excluding patients with a history of COVID-19, in subgroup analyses restricted to patients who completed the two-dose BNT162b2 regimen, and in patients receiving in-center hemodialysis. SARS-CoV-2 antibodies were detected in 59.4% of 244 patients who received Ad26.COV2.S. CONCLUSIONS: In a large real-world cohort of patients on dialysis, no difference was detected in clinical effectiveness of BNT162b2 and Ad26.COV2.S over the first 6 months postvaccination, despite an inconsistent antibody response to the latter.
Authors: Galit Alter; Jingyou Yu; Jinyan Liu; Abishek Chandrashekar; Erica N Borducchi; Lisa H Tostanoski; Katherine McMahan; Catherine Jacob-Dolan; David R Martinez; Aiquan Chang; Tochi Anioke; Michelle Lifton; Joseph Nkolola; Kathryn E Stephenson; Caroline Atyeo; Sally Shin; Paul Fields; Ian Kaplan; Harlan Robins; Fatima Amanat; Florian Krammer; Ralph S Baric; Mathieu Le Gars; Jerald Sadoff; Anne Marit de Groot; Dirk Heerwegh; Frank Struyf; Macaya Douoguih; Johan van Hoof; Hanneke Schuitemaker; Dan H Barouch Journal: Nature Date: 2021-06-09 Impact factor: 49.962
Authors: Shuchi Anand; Maria E Montez-Rath; Jialin Han; Pablo Garcia; LinaCel Cadden; Patti Hunsader; Russell Kerschmann; Paul Beyer; Mary Dittrich; Geoffrey A Block; Scott D Boyd; Julie Parsonnet; Glenn M Chertow Journal: J Am Soc Nephrol Date: 2021-06-11 Impact factor: 14.978
Authors: Adam G Walker; Scott Sibbel; Curtis Wade; Nick Moulton; Gilbert Marlowe; Amy Young; Stephen Z Fadem; Steven M Brunelli Journal: Kidney Med Date: 2021-02-05
Authors: Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks Journal: N Engl J Med Date: 2020-12-30 Impact factor: 91.245
Authors: Jerald Sadoff; Glenda Gray; An Vandebosch; Vicky Cárdenas; Georgi Shukarev; Beatriz Grinsztejn; Paul A Goepfert; Carla Truyers; Hein Fennema; Bart Spiessens; Kim Offergeld; Gert Scheper; Kimberly L Taylor; Merlin L Robb; John Treanor; Dan H Barouch; Jeffrey Stoddard; Martin F Ryser; Mary A Marovich; Kathleen M Neuzil; Lawrence Corey; Nancy Cauwenberghs; Tamzin Tanner; Karin Hardt; Javier Ruiz-Guiñazú; Mathieu Le Gars; Hanneke Schuitemaker; Johan Van Hoof; Frank Struyf; Macaya Douoguih Journal: N Engl J Med Date: 2021-04-21 Impact factor: 176.079
Authors: Jeffrey G Mulhern; Amit Fadia; Ruchir Patel; Linda H Ficociello; Joanna Willetts; Ines A Dahne-Steuber; Melanie C Pollan; Claudy Mullon; Josephine DeLisi; Curtis Johnson; Chance Mysayphonh; Robert J Kossmann; Michael S Anger; Jeffrey L Hymes Journal: Clin J Am Soc Nephrol Date: 2021-07-26 Impact factor: 8.237
Authors: Dena E Cohen; Scott Sibbel; Gilbert Marlowe; Kelsey Bludorn; Dawn Miller; Tara Kelley; Jeffrey Connaire; Amy Young; Francesca Tentori; Steven M Brunelli Journal: J Am Soc Nephrol Date: 2021-07-02 Impact factor: 14.978
Authors: Duvuru Geetha; Andreas Kronbichler; Megan Rutter; Divya Bajpai; Steven Menez; Annemarie Weissenbacher; Shuchi Anand; Eugene Lin; Nicholas Carlson; Stephen Sozio; Kevin Fowler; Ray Bignall; Kathryn Ducharlet; Elliot K Tannor; Eranga Wijewickrama; Muhammad I A Hafidz; Vladimir Tesar; Robert Hoover; Deidra Crews; Charles Varnell; Lara Danziger-Isakov; Vivekanand Jha; Sumit Mohan; Chirag Parikh; Valerie Luyckx Journal: Nat Rev Nephrol Date: 2022-08-24 Impact factor: 42.439